Tenaya Therapeutics, Inc. Financials
This page shows Tenaya Therapeutics, Inc. (TNYA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash replenishment, not revenue generation, is driving Tenaya’s model as R&D-heavy losses are repeatedly offset by financing.
From FY2023 to FY2025, operating cash burn improved from-$102.1M to-$68.3M while cash on hand rose from$45.7M to$100.5M , but that stronger liquidity came with$108.4M of financing cash inflow rather than internal cash generation. The non-obvious point is that the balance sheet recovery reflects both tighter spending and fresh capital, and the stronger cash position was paired with a much larger share count.
The expense base is still overwhelmingly research-led: FY2025 R&D spending was
FY2025 free cash flow of
Financial Health Signals
Tenaya Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Tenaya Therapeutics, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Tenaya Therapeutics, Inc. reported a net loss of $90.6M while operations used $68.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Tenaya Therapeutics, Inc.'s EBITDA was -$84.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.0% from the prior year.
Tenaya Therapeutics, Inc. reported -$90.6M in net income in fiscal year 2025. This represents an increase of 18.5% from the prior year.
Tenaya Therapeutics, Inc. earned -$0.59 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Tenaya Therapeutics, Inc. recorded an outflow of $68.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 24.7% from the prior year.
Tenaya Therapeutics, Inc. held $100.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Tenaya Therapeutics, Inc.'s ROE was -73.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 46.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Tenaya Therapeutics, Inc. invested $68.6M in research and development in fiscal year 2025. This represents a decrease of 20.9% from the prior year.
Tenaya Therapeutics, Inc. invested $618K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.7% from the prior year.
Not reported for fiscal year 2025.
TNYA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $68.6M-20.9% | $86.7M-11.5% | $98.0M+3.7% | $94.5M+73.8% | $54.4M+74.9% | $31.1M |
| SG&A Expenses | N/A | $24.7M-15.3% | $29.2M-11.9% | $33.2M+6.7% | $31.1M+68.8% | $18.4M+135.7% | $7.8M |
| Operating Income | N/A | -$93.3M+19.5% | -$115.9M+11.6% | -$131.2M-4.4% | -$125.6M-72.5% | -$72.8M-87.1% | -$38.9M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$90.6M+18.5% | -$111.1M+10.4% | -$124.1M-0.3% | -$123.7M-70.1% | -$72.7M-89.4% | -$38.4M |
| EPS (Diluted) | — | -$0.59 | -$1.31+22.0% | -$1.68 | -$2.76 | -$4.10 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TNYA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $146.9M+22.5% | $119.9M-29.7% | $170.5M-38.9% | $278.9M-11.2% | $314.2M+112.1% | $148.2M |
| Current Assets | $105.6M+56.7% | $67.4M-39.6% | $111.6M-42.4% | $193.8M-24.1% | $255.4M+96.5% | $130.0M |
| Cash & Equivalents | $100.5M+2225.9% | $4.3M-90.5% | $45.7M-52.1% | $95.3M+149.9% | $38.1M-70.3% | $128.5M |
| Total Liabilities | $23.7M-12.7% | $27.1M-12.9% | $31.1M-12.6% | $35.6M-0.3% | $35.7M-84.5% | $229.5M |
| Current Liabilities | $15.4M-3.4% | $16.0M-29.7% | $22.7M-6.2% | $24.2M+11.4% | $21.8M+331.9% | $5.0M |
| Total Equity | $123.3M+32.8% | $92.9M-33.4% | $139.4M-42.7% | $243.4M-12.6% | $278.5M+442.5% | -$81.3M |
| Retained Earnings | -$605.0M-17.6% | -$514.4M-27.6% | -$403.3M-44.4% | -$279.2M-79.5% | -$155.5M-87.8% | -$82.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TNYA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$52.3M | -$68.3M+24.6% | -$90.5M+11.3% | -$102.1M+2.3% | -$104.4M-71.7% | -$60.8M-71.6% | -$35.4M |
| Capital Expenditures | $263K | $618K-39.7% | $1.0M-17.3% | $1.2M-94.0% | $20.6M-17.9% | $25.1M+157.3% | $9.8M |
| Free Cash Flow | -$52.6M | -$68.9M+24.7% | -$91.5M+11.4% | -$103.3M+17.4% | -$125.1M-45.5% | -$85.9M-90.1% | -$45.2M |
| Investing Cash Flow | $8.6M | $56.1M+4858.7% | $1.1M-97.7% | $48.7M-41.8% | $83.7M+135.1% | -$238.6M-3303.2% | -$7.0M |
| Financing Cash Flow | $59.1M | $108.4M+127.0% | $47.7M+1079.3% | $4.0M-94.8% | $77.8M-62.8% | $209.0M+41.9% | $147.3M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | $13K+1200.0% | $1K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TNYA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | -73.5%+46.2pp | -119.7%-30.7pp | -89.0%-38.2pp | -50.8%-24.7pp | -26.1% | N/A |
| Return on Assets | -61.7%+31.0pp | -92.7%-19.9pp | -72.8%-28.4pp | -44.3%-21.2pp | -23.2%+2.8pp | -25.9% |
| Current Ratio | 6.84+2.6x | 4.22-0.7x | 4.91-3.1x | 7.99-3.7x | 11.73-14.1x | 25.78 |
| Debt-to-Equity | 0.19-0.1x | 0.29+0.1x | 0.22+0.1x | 0.150.0x | 0.13 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Tenaya Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Tenaya Therapeutics, Inc. profitable?
No, Tenaya Therapeutics, Inc. (TNYA) reported a net income of -$90.6M in fiscal year 2025.
What is Tenaya Therapeutics, Inc.'s EBITDA?
Tenaya Therapeutics, Inc. (TNYA) had EBITDA of -$84.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Tenaya Therapeutics, Inc.'s return on equity (ROE)?
Tenaya Therapeutics, Inc. (TNYA) has a return on equity of -73.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Tenaya Therapeutics, Inc.'s free cash flow?
Tenaya Therapeutics, Inc. (TNYA) recorded an outflow of $68.9M in free cash flow during fiscal year 2025. This represents a 24.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tenaya Therapeutics, Inc.'s operating cash flow?
Tenaya Therapeutics, Inc. (TNYA) recorded an outflow of $68.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tenaya Therapeutics, Inc.'s total assets?
Tenaya Therapeutics, Inc. (TNYA) had $146.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tenaya Therapeutics, Inc.'s capital expenditures?
Tenaya Therapeutics, Inc. (TNYA) invested $618K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Tenaya Therapeutics, Inc. spend on research and development?
Tenaya Therapeutics, Inc. (TNYA) invested $68.6M in research and development during fiscal year 2025.
What is Tenaya Therapeutics, Inc.'s current ratio?
Tenaya Therapeutics, Inc. (TNYA) had a current ratio of 6.84 as of fiscal year 2025, which is generally considered healthy.
What is Tenaya Therapeutics, Inc.'s debt-to-equity ratio?
Tenaya Therapeutics, Inc. (TNYA) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Tenaya Therapeutics, Inc.'s return on assets (ROA)?
Tenaya Therapeutics, Inc. (TNYA) had a return on assets of -61.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Tenaya Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Tenaya Therapeutics, Inc. (TNYA) had $100.5M in cash against an annual operating cash burn of $68.3M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Tenaya Therapeutics, Inc.'s Piotroski F-Score?
Tenaya Therapeutics, Inc. (TNYA) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Tenaya Therapeutics, Inc.'s earnings high quality?
Tenaya Therapeutics, Inc. (TNYA) reported a net loss of $90.6M while operations used $68.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.